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Abstract
The aim of this Global Allergy and Asthma European Network (GA2LEN) con-
sensus report is to provide recommendations and suggestions for assessing
patient-reported outcomes (PROs) including health-related quality of life in
patients with urticaria. We recommend that PROs should be used both in clinical
trials and routine practice for the evaluation of urticaria patients. We suggest that
PROs should be considered as the primary outcome of future clinical trials. Two
validated and disease-speciﬁc instruments for assessing PROs are available, the
urticaria activity score (for symptoms) and the chronic urticaria questionnaire on
quality of life CU-Q2oL. This latter tool, CU-Q2oL, is available in many lan-
guages and should be preferred, where available, over more generic instruments
for assessing urticaria-speciﬁc effects on quality of life. CU-Q2oL is only suited
for the investigation of patients with chronic spontaneous urticaria. Similar
instruments for other forms of urticaria have yet to be developed and validated.
Also, tools for assessing other chronic spontaneous urticaria PROs besides quality
of life and symptoms are needed.
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Urticaria is a common skin disorder, characterized by itchy
wheals and/or angioedema (1, 2). Many patients with
urticaria remain afﬂicted beyond the acute stage by the con-
dition, often for years, and nonacute urticaria has repeatedly
been found to have a substantial impact on patient quality-
of-life (QoL) (3–9). Recent reports have shown that patients
with severe chronic spontaneous urticaria, mainly nonre-
sponders to standard therapy, exhibit low levels of satisfac-
tion with their physicians and treatments and that they
expect their physicians to provide them with other and more
effective therapies (10, 11). To better understand the impact
of urticaria on affected patients and patients’ views of their
disease and its consequences, patient-reported outcomes
(PROs) other than symptoms need to be consistently assessed
in both clinical research and routine patient care (12, 13).
Until now, very few randomized controlled trials have been
published in which health-related QoL was assessed. Reviews
that summarize urticaria patients’ perspectives on the effects
of their disease and treatment are largely missing. Currently,
no randomized controlled trials in urticaria consider PROs
other than symptoms and/or QoL. The consensus reached by
the GA2LEN task force for PROs assessment in clinical trials
with allergic patients (14) and more speciﬁcally in respiratory
allergy (15) supports the aim of this new Global Allergy and
Asthma European Network (GA2LEN) consensus report. It
is to provide information on the available instruments for
PROs assessment in urticaria, to give recommendations and
suggestions for PROs evaluation in clinical trials and routine
medical practice, and to present areas of need for further
research on PROs in urticaria.
PROs evaluation in patients with urticaria as primary
and secondary outcome in clinical trials
Most clinical trials in spontaneous urticaria use symptom
scores to assess disease activity and response to treatment,
whereas for inducible urticaria, trigger thresholds are among
the most common outcome parameters. As yet, only 10 trials
have been performed, which analyze health-related QoL, in
patients with chronic spontaneous urticaria. In six of these 10
trials health-related QoL, assessment is a secondary outcome.
As a trial’s sample size calculation is based on the primary
outcome, health-related QoL results from studies in which
QoL is a secondary outcome which should be carefully evalu-
ated.
As urticaria may have a substantial impact on the daily
life of patients, we recommend the development of clinical
trials in which PROs are evaluated as primary outcome of
the study. A coprimary outcome in conjunction with other
objective or physician-rated measurements, or a secondary
outcome whose analysis is considered following a hierarchical
sequence (16), is also recommended.
When PROs are used as secondary outcome, the sample
size calculated for the primary endpoint should be adequate
for demonstrating hypotheses made a priori on the PROs
assessment (17). So far only one therapeutic trial in chronic
spontaneous urticaria has used QoL as a primary outcome
(18). When PROs evaluation is the end-point of an urticaria
trial, an overview of the previous existing evidence, the
reason for choosing this endpoint and the expected results
must be provided. If exclusion criteria comprise patient-
related factors that could inﬂuence PROs assessment, this
must be clearly stated. Relevant patient-related factors
include mood, stress, alexithymia (i.e. the inability to express
feelings with words), coping, psychosomatic comorbidity and
inﬂuences, personality traits, or psychological variables.
QoL assessment in patients with urticaria
Quality-of-life in patients with chronic spontaneous urti-
caria has been measured with several different tools
(Table 1). The use of generic tools allows for comparison
of QoL impairment in patients with urticaria and patients
with other conditions. Generic tools are not as sensitive as
dermatology-speciﬁc or disease-speciﬁc instruments in
detecting changes of QoL as a result of modiﬁcations in
disease activity. Dermatology-speciﬁc instruments are espe-
cially helpful for comparing the impact of different diseases
on patients’ QoL. However, they are not as responsive to
changes in QoL following modiﬁcations in the urticaria
activity as disease-speciﬁc instruments. The chronic urticaria
questionnaire on quality of life (CU-Q2oL) is a unique dis-
ease-speciﬁc instrument for chronic spontaneous urticaria.
It has been shown to be superior to less speciﬁc instru-
ments in measuring the impact of the disease on patients’
QoL. Also it was superior in comparing QoL impairment
in different subsets of patients with chronic spontaneous
urticaria and in assessing changes in QoL over time, e.g. in
response to treatment. The use of symptom-speciﬁc instru-
ments in patients with urticaria (e.g. ItchyQoL for assessing
the impact of itch on QoL impairment (19) has not yet
been reported (Tables 1 and 2).
Table 1 Examples for quality-of-life (QoL) instruments used in
chronic spontaneous urticaria
Category Instrument References
Generic Medical Outcomes
Study (MOS) SF-36
(8, 29)
Nottingham Health
Profile (NHP)
(30, 31)
World Health
Organisation
QOL-Brief
(WHOQoL-BREF)
(32, 33)
Dermatology-specific Dermatological Life
Quality Index (DLQI)
(4, 9, 34–36)
Skindex (3, 5, 10)
VQ Dermato (18, 37, 38)
Disease-specific Chronic Urticaria –
Quality of Life
Questionnaire
(CU-Q2oL)
(3, 6, 7, 39, 40)
Symptom-specific –
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Methods for PROs evaluation in clinical urticaria trials
The evaluation of PROs in clinical trials should make use of
evidence-based medical protocols and procedures. If the trial
is aimed at the investigation of the efﬁcacy of a drug, a dou-
ble blind randomised controlled design is recommended. If
the trial investigates another kind of intervention besides
drugs, a randomised controlled trial is recommended, with a
double blind design if possible. Open-label studies, in which
patients and investigators are aware of the assigned therapy,
may bias the assessment of PROs.
The length of the trial will be determined by the nature of
the disease (acute/chronic); however, the length should also be
in line with the investigated PROs. The duration of previous
studies performed to assess health-related QoL in chronic
spontaneous urticaria is between 3 and 12 weeks. As chronic
spontaneous urticaria – by deﬁnition – persists longer than
6 weeks, PROs assessment should be adapted to this duration.
Also, the duration of trials should reﬂect that CU-Q2oL (2, 11)
as well as generic tools such as the Dermatological Life Quality
Index (DLQI) or Skindex provide information on the patient’s
QoL during the previous one (DLQI, SKINDEX) or 2 weeks
(CU-Q2oL). In long-term trials, a periodical QoL assessment,
taking into account the tool recall period, may provide a more
comprehensive patient’s perspective evaluation. It is important
however that such a questionnaire is not submitted too often
to the patient, because remembrance of the previous answers
may bias responses.
Choice of the PROs tool in clinical urticaria trials
Currently, only two validated and urticaria-speciﬁc tools for
PROs assessment are available: the urticaria activity score
(UAS; for symptoms) and CU-Q2oL (for health-related qual-
ity of life). Both tools are for chronic spontaneous urticaria
only. Instruments for PROs assessment in patients with acute
spontaneous urticaria or inducible urticaria are missing and
have yet to be developed.
For chronic spontaneous urticaria, the UAS and CU-
Q2oL, where available, should be preferred over the use of
nonvalidated tools. In addition, the choice of the instrument
must be made according to the aim of the study (i.e. if the
impact on sleep is relevant, a tool suited for sleep assessment
must be used) and the reason of the choice must be provided.
When PROs assessment is done by use of a symptoms score,
the UAS should be used according to current EAACI/
GA2LEN/EDF/WAO guidelines. Brieﬂy, daily scores for
numbers of wheals and intensity of pruritus are recorded and
added for at least four consecutive days. Commonly, UAS
scores of seven consecutive days, i.e. the UAS7, are used.
Patient-reported outcomes evaluation tools must also be
chosen according to the characteristics of the study popula-
tion in terms of age (proper age-related tool), socio-cultural
background, and diseases phenotypes. Of the 10 published
trials that evaluated health-related QoL in chronic sponta-
neous urticaria, eight used the DLQI or the SKINDEX,
i.e. skin disease-speciﬁc questionnaires. Although they are
well-validated tools, they have limitations as they are not
speciﬁcally developed for patients with chronic spontaneous
urticaria, but for dermatological diseases in general. In fact,
they have been used for patients suffering from various
clinical dermatological conditions such as eczema, lipodys-
trophy, skin cancer, ichthyosis, psoriasis, melasma, hyper-
hidrosis, and acne (20–27).
While highly speciﬁc tools targeted to chronic spontaneous
urticaria (such as CU-Q2oL) are ideally suited to measure the
effects of changes in disease activity, they do not allow for
the comparison of QoL impairment with other disorders and
Table 2 Quality-of-life (QoL) instruments and their use in urticaria trials and routine patient treatment
Objective
Instrument category (Example)
Generic (SF-12/SF-36,
NHP, WHOQoL-Bref)
Dermatology-specific
(DLQI, Skindex, VQ-Dermato)
Disease-specific
(CU-Q2oL)
Symptom-specific
(ItchyQol)
Compare QoL in patients
with different diseases
+++ ) ) )
Compare QoL in patients
with different skin conditions
+ +++ ) )
Compare QoL in patients
with different urticaria
subpopulations
+ + +++ + ) +++
Monitor QoL over time )/(+) + +++ + ) +++
Monitor QoL in response to
treatment
)/(+) + +++ + ) +++
Assess symptom-specific
impact on QoL
) ) ) +++
) not suited; (+) somewhat/sometimes suited; + suited, ++ well suited, +++ ideally suited.
CU-Q2oL, chronic urticaria questionnaire on quality of life.
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can therefore not be used to rate the condition’s impact on
QoL within a group of disorders (allergic diseases or skin dis-
orders, for instance). Furthermore, QoL is affected by many
factors of which the presence of a disease is only one. A dis-
ease-speciﬁc QoL instrument is very sensitive in picking up
the impact of the respective disease on QoL. But it is less
sensitive than more general tools in picking up the impact of
other factors that inﬂuence QoL. For instance, effects on
QoL of a new drug for urticaria that inﬂuences a QoL
dimension not usually affected by chronic spontaneous urti-
caria may be overlooked in a trial using a speciﬁc tool, but
not by a more generic instrument.
When the impact on PROs including health-related QoL
of a speciﬁc symptom needs to be explored, a symptom-
speciﬁc tool should be used (when available) in addition to a
disease-speciﬁc questionnaire. For example, ItchyQoL, a
symptom-speciﬁc questionnaire for assessing QoL-impairment
due to pruritus, and CU-Q2oL should be used to determine
the impact of pruritus on patients with chronic spontaneous
urticaria (Table 2).
The high prevalence of psychosomatic comorbidity and
inﬂuences and their signiﬁcant burden on patients’ QoL
should be considered when investigating chronic spontaneous
urticaria (5, 28, 29). The role of psychological characteristics
and personality traits in determining the subjective experience
of patients with chronic spontaneous urticaria still remains
largely unexplored (30, 31).
In trials assessing the effects of an intervention, the choice
of the PROs tool will be made according to the expected
intervention effects. Whenever available a tool speciﬁc for the
outcome (e.g. sleep, satisfaction, etc.) should be used.
PROs assessment in routine clinical practice
Both, the UAS and the CU-Q2oL are suited and recom-
mended for the use in routine clinical practice. These PROs
tools can be used to determine disease activity impact as well
as changes in disease activity impact including those in
response to therapy. However, more generic instruments such
as those adapted for chronic skin disorders may also be used.
Unmet needs in PROs assessment in urticaria
1 There are currently no tools a) for the assessment of other
PROs besides QoL and symptoms in chronic spontaneous
urticaria, b) for PROs assessment in patients with
inducible urticaria, c) for PROs assessment in children
and adolescents with urticaria or their parents, and d) for
PROs assessment in partners of patients with urticaria.
2 The impact of doctor/patient communication on PROs
needs investigation as currently urticaria patients’ and
doctors’ view on the quality of their relationship differ
signiﬁcantly.
3 Minimal important differences for PROs instruments as
well as the suitability of PROs tools to categorize disease
activity as mild, moderate, or severe remain to be investi-
gated in detail and published.
4 The assessment of relationships between different PROs
and psychological variables is needed.
5 The transvalidation in different languages, and not only
the translation, of the main instruments for PROs assess-
ment, or the generation of international instruments is
needed.
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